Loading...

We've got a brand new version of Simply Wall St! Try it out

Innovative Pharmaceutical Biotech

DB:FRHN
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FRHN
DB
HK$432M
Market Cap
  1. Home
  2. DE
  3. Capital Goods
Company description

Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong. The last earnings update was 106 days ago. More info.


Add to Portfolio Compare Print
FRHN Share Price and Events
7 Day Returns
-7%
DB:FRHN
7%
DE Trade Distributors
0.8%
DE Market
1 Year Returns
-21.4%
DB:FRHN
6.9%
DE Trade Distributors
9%
DE Market
FRHN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Innovative Pharmaceutical Biotech (FRHN) -7% -4.3% -3.2% -21.4% -55.4% -
DE Trade Distributors 7% 8.4% 16.8% 6.9% -1.2% 8.4%
DE Market 0.8% 6.3% 14.4% 9% 14.5% 21.8%
1 Year Return vs Industry and Market
  • FRHN underperformed the Trade Distributors industry which returned 6.9% over the past year.
  • FRHN underperformed the Market in Germany which returned 9% over the past year.
Price Volatility
FRHN
Industry
5yr Volatility vs Market

FRHN Value

 Is Innovative Pharmaceutical Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Innovative Pharmaceutical Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Innovative Pharmaceutical Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Innovative Pharmaceutical Biotech. This is due to cash flow or dividend data being unavailable. The share price is €0.033.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Innovative Pharmaceutical Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Innovative Pharmaceutical Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:FRHN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in HKD HK$-0.18
SEHK:399 Share Price ** SEHK (2019-11-13) in HKD HK$0.3
Germany Trade Distributors Industry PE Ratio Median Figure of 7 Publicly-Listed Trade Distributors Companies 16.14x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 19.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Innovative Pharmaceutical Biotech.

DB:FRHN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:399 Share Price ÷ EPS (both in HKD)

= 0.3 ÷ -0.18

-1.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innovative Pharmaceutical Biotech is loss making, we can't compare its value to the DE Trade Distributors industry average.
  • Innovative Pharmaceutical Biotech is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Innovative Pharmaceutical Biotech's expected growth come at a high price?
Raw Data
DB:FRHN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Trade Distributors Industry PEG Ratio Median Figure of 32 Publicly-Listed Trade Distributors Companies 1.82x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Innovative Pharmaceutical Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Innovative Pharmaceutical Biotech's assets?
Raw Data
DB:FRHN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in HKD HK$-0.05
SEHK:399 Share Price * SEHK (2019-11-13) in HKD HK$0.3
Germany Trade Distributors Industry PB Ratio Median Figure of 10 Publicly-Listed Trade Distributors Companies 1.19x
Germany Market PB Ratio Median Figure of 577 Publicly-Listed Companies 1.83x
DB:FRHN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:399 Share Price ÷ Book Value per Share (both in HKD)

= 0.3 ÷ -0.05

-5.76x

* Primary Listing of Innovative Pharmaceutical Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innovative Pharmaceutical Biotech has negative assets, we can't compare the value of its assets to the DE Trade Distributors industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Innovative Pharmaceutical Biotech's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Trade Distributors industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Innovative Pharmaceutical Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Trade Distributors industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Trade Distributors industry average (and greater than 0)? (1 check)
  5. Innovative Pharmaceutical Biotech has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FRHN Future Performance

 How is Innovative Pharmaceutical Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovative Pharmaceutical Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.6%
Expected Trade Distributors industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Innovative Pharmaceutical Biotech expected to grow at an attractive rate?
  • Unable to compare Innovative Pharmaceutical Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Innovative Pharmaceutical Biotech's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Innovative Pharmaceutical Biotech's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:FRHN Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Trade Distributors Industry Earnings Growth Rate Market Cap Weighted Average 13.6%
Europe Trade Distributors Industry Revenue Growth Rate Market Cap Weighted Average 3.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:FRHN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:FRHN Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2019-03-31 19 -29 -260
2018-12-31 17 3 -258
2018-09-30 16 35 -256
2018-06-30 16 10 -243
2018-03-31 16 -15 -231
2017-12-31 14 -17 -237
2017-09-30 13 -19 -243
2017-06-30 11 51 -206
2017-03-31 9 120 -170
2016-12-31 10 48 -196
2016-09-30 11 -24 -223
2016-06-30 16 -79 -230

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Innovative Pharmaceutical Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Innovative Pharmaceutical Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:FRHN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Innovative Pharmaceutical Biotech Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:FRHN Past Financials Data
Date (Data in HKD Millions) EPS *
2019-03-31 -0.18
2018-12-31 -0.18
2018-09-30 -0.17
2018-06-30 -0.17
2018-03-31 -0.16
2017-12-31 -0.16
2017-09-30 -0.17
2017-06-30 -0.14
2017-03-31 -0.12
2016-12-31 -0.13
2016-09-30 -0.15
2016-06-30 -0.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Innovative Pharmaceutical Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Innovative Pharmaceutical Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Capital Goods companies here
  2. Innovative Pharmaceutical Biotech's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Innovative Pharmaceutical Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Innovative Pharmaceutical Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FRHN Past Performance

  How has Innovative Pharmaceutical Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Innovative Pharmaceutical Biotech's growth in the last year to its industry (Trade Distributors).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Innovative Pharmaceutical Biotech does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Innovative Pharmaceutical Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Innovative Pharmaceutical Biotech's 1-year growth to the DE Trade Distributors industry average as it is not currently profitable.
Earnings and Revenue History
Innovative Pharmaceutical Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Innovative Pharmaceutical Biotech Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:FRHN Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 18.59 -260.27 26.74 1.93
2018-12-31 17.36 -257.96 29.53 1.30
2018-09-30 16.14 -255.66 32.31 0.67
2018-06-30 15.97 -243.35 29.03 0.67
2018-03-31 15.81 -231.05 25.75 0.67
2017-12-31 14.34 -237.11 22.13 0.65
2017-09-30 12.87 -243.17 18.51 0.63
2017-06-30 11.03 -206.48 20.63 0.63
2017-03-31 9.19 -169.79 22.75 0.63
2016-12-31 10.16 -196.24 26.96 0.99
2016-09-30 11.14 -222.70 31.17 1.35
2016-06-30 15.52 -229.78 30.72 1.35
2016-03-31 19.91 -236.87 30.26 1.35
2015-12-31 25.26 -213.51 25.11 3.33
2015-09-30 30.61 -190.15 19.96 5.30
2015-06-30 32.29 -320.92 23.92 5.30
2015-03-31 33.98 -451.68 27.89 5.30
2014-09-30 41.49 -890.68 32.95
2014-06-30 38.84 -729.99 34.99
2014-03-31 36.18 -569.30 37.03
2013-12-31 31.44 -522.50 54.23
2013-09-30 20.74 -297.67 52.71
2013-06-30 7.75 -45.27 45.42
2013-03-31 4.98 -87.84 34.25
2012-12-31 1.37 -116.88 33.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Innovative Pharmaceutical Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Innovative Pharmaceutical Biotech has efficiently used its assets last year compared to the DE Trade Distributors industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Innovative Pharmaceutical Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Innovative Pharmaceutical Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Trade Distributors industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Innovative Pharmaceutical Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FRHN Health

 How is Innovative Pharmaceutical Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Innovative Pharmaceutical Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Innovative Pharmaceutical Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Innovative Pharmaceutical Biotech's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Innovative Pharmaceutical Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Innovative Pharmaceutical Biotech Company Filings, last reported 7 months ago.

DB:FRHN Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 794.81 755.46 17.06
2018-12-31 794.81 755.46 17.06
2018-09-30 892.86 648.32 31.91
2018-06-30 892.86 648.32 31.91
2018-03-31 1,066.83 628.08 56.47
2017-12-31 1,066.83 628.08 56.47
2017-09-30 1,149.61 570.96 85.60
2017-06-30 1,149.61 570.96 85.60
2017-03-31 1,298.33 542.38 61.32
2016-12-31 1,298.33 542.38 61.32
2016-09-30 1,404.32 493.69 96.89
2016-06-30 1,404.32 493.69 96.89
2016-03-31 1,479.02 473.43 32.46
2015-12-31 1,479.02 473.43 32.46
2015-09-30 1,627.02 435.49 147.45
2015-06-30 1,627.02 435.49 147.45
2015-03-31 1,601.46 420.60 191.19
2014-09-30 1,573.09 307.44 205.33
2014-06-30 1,573.09 307.44 205.33
2014-03-31 672.22 52.23 298.22
2013-12-31 765.68 50.18 204.96
2013-09-30 765.68 50.18 204.96
2013-06-30 444.36 36.95 356.51
2013-03-31 444.36 36.95 356.51
2012-12-31 382.64 14.18 332.26
  • Innovative Pharmaceutical Biotech's level of debt (95%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (8.1% vs 95% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Innovative Pharmaceutical Biotech has less than a year of cash runway based on current free cash flow.
  • Innovative Pharmaceutical Biotech has less than a year of cash runway if free cash flow continues to reduce at historical rates of -40.3% each year.
X
Financial health checks
We assess Innovative Pharmaceutical Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Innovative Pharmaceutical Biotech has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FRHN Dividends

 What is Innovative Pharmaceutical Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Innovative Pharmaceutical Biotech dividends.
If you bought €2,000 of Innovative Pharmaceutical Biotech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Innovative Pharmaceutical Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Innovative Pharmaceutical Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:FRHN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Trade Distributors Industry Average Dividend Yield Market Cap Weighted Average of 6 Stocks 2.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 2.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Innovative Pharmaceutical Biotech has not reported any payouts.
  • Unable to verify if Innovative Pharmaceutical Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Innovative Pharmaceutical Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Innovative Pharmaceutical Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Innovative Pharmaceutical Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Innovative Pharmaceutical Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Innovative Pharmaceutical Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FRHN Management

 What is the CEO of Innovative Pharmaceutical Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Innovative Pharmaceutical Biotech has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the Innovative Pharmaceutical Biotech management team in years:

6.5
Average Tenure
55
Average Age
  • The average tenure for the Innovative Pharmaceutical Biotech management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rong Tang

TITLE
Executive Director
COMPENSATION
HK$548K
AGE
52

Yuan Xing Gao

TITLE
Executive Director
COMPENSATION
HK$1M
AGE
64

He Huang

TITLE
Executive Director
COMPENSATION
HK$668K
AGE
38

Yumin Mao

TITLE
Honorary Chairman & Chief Scientific Adviser
AGE
67
TENURE
9.2 yrs

Hon Yin Poon

TITLE
Financial Controller & Company Secretary
AGE
53
TENURE
6.5 yrs

Qi Dong

TITLE
Sales Head of the Group
AGE
45

Wei Ping Yu

TITLE
Joint Chairman to the Department of Innovation & Strategic Development and Advisor
AGE
61

Jie Gu

TITLE
Adviser and Joint Chairman to the Department of Innovation & Strategic Development
AGE
54
TENURE
3.9 yrs

Yi Xie

TITLE
Chief Executive of United Gane Holdings Limited
AGE
56

Dong Hui

TITLE
General Manager of the Group and Director of CJV
AGE
57
Board of Directors Tenure

Average tenure and age of the Innovative Pharmaceutical Biotech board of directors in years:

8.4
Average Tenure
62.5
Average Age
  • The tenure for the Innovative Pharmaceutical Biotech board of directors is about average.
Board of Directors

Nian Jiang

TITLE
Chairman
COMPENSATION
HK$60K
AGE
65
TENURE
8.4 yrs

Rong Tang

TITLE
Executive Director
COMPENSATION
HK$548K
AGE
52
TENURE
5.2 yrs

Yuan Xing Gao

TITLE
Executive Director
COMPENSATION
HK$1M
AGE
64
TENURE
3.8 yrs

He Huang

TITLE
Executive Director
COMPENSATION
HK$668K
AGE
38
TENURE
2.8 yrs

Yumin Mao

TITLE
Honorary Chairman & Chief Scientific Adviser
AGE
67
TENURE
9.2 yrs

Dong Hui

TITLE
General Manager of the Group and Director of CJV
AGE
57

Weijun Chen

TITLE
Independent Non-Executive Director
COMPENSATION
HK$80K
AGE
61
TENURE
10 yrs

Zhihong Zhang

TITLE
Independent Non-Executive Director
COMPENSATION
HK$60K
AGE
79
TENURE
8.4 yrs

Yanmin Wu

TITLE
Non-Executive Director
COMPENSATION
HK$152K
AGE
42
TENURE
8.4 yrs

Rongliang Wang

TITLE
Independent Non-Executive Director
COMPENSATION
HK$60K
AGE
70
TENURE
8.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Innovative Pharmaceutical Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Innovative Pharmaceutical Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FRHN News

Simply Wall St News

FRHN Company Info

Description

Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong. The company also engages in the trading of beauty equipment and products; distribution of bio-industrial products; and securities investment activities. In addition, it is involved in the research, development, and commercialization of oral insulin products; and engages in the healthcare management business. The company was formerly known as United Gene High-Tech Group Limited and changed its name to Innovative Pharmaceutical Biotech Limited in September 2015. Innovative Pharmaceutical Biotech Limited is headquartered in Sheung Wan, Hong Kong.

Details
Name: Innovative Pharmaceutical Biotech Limited
FRHN
Exchange: DB
Founded:
HK$50,128,377
1,464,193,024
Website: http://www.ipb.asia
Address: Innovative Pharmaceutical Biotech Limited
West Tower Shun Tak Centre,
Unit No. 2111,
Sheung Wan,
Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 399 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 23. Aug 2000
DB FRHN Ordinary Shares Deutsche Boerse AG DE EUR 23. Aug 2000
Number of employees
Current staff
Staff numbers
23
Innovative Pharmaceutical Biotech employees.
Industry
Trading Companies and Distributors
Capital Goods
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/13 21:10
End of day share price update: 2019/11/13 00:00
Last earnings filing: 2019/07/30
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.